What's in Swedish Orphan Biovitrum (Sobi)'s pipeline?

Swedish Orphan Biovitrum (Sobi) has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Swedish Orphan Biovitrum (Sobi)'s portfolio?

Top competitors by shared drug class: ASTRAZENECA LP, AbbVie, AstraZeneca, Bayer, BeiGene.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sobi.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Swedish Orphan Biovitrum (Sobi) — Portfolio Competitive Intelligence Brief

Swedish Orphan Biovitrum (Sobi) (SOBI.ST) pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

SOBI.ST (Nasdaq Stockholm) 1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Vonjo	PACRITINIB	marketed	Kinase Inhibitor [EPC]	Tyrosine-protein kinase JAK2	Oncology	2022-01-01

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

ASTRAZENECA LP · 1 shared drug class
AbbVie · 1 shared drug class
AstraZeneca · 1 shared drug class
Bayer · 1 shared drug class
BeiGene · 1 shared drug class
Beigene Usa Inc · 1 shared drug class
Blueprint Medicines · 1 shared drug class
· 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Swedish Orphan Biovitrum (Sobi):

Cite this brief

Drug Landscape (2026). Swedish Orphan Biovitrum (Sobi) — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sobi. Accessed 2026-05-13.